{
  "drug pillars count": "4",
  "therapy type": [
    {
      "ID": "01",
      "therapy abbreviation": "ARNI",
      "therapy name": "angiotensin receptor-neprilysin inhibitor",
      "entry info": {
        "medication": {
          "clinical name": "sacubitril/valsartan",
          "brand name": "Entresto",
          "indication": "to reduce risk of CV death and HF hospitalization in patients w/ chronic HF",
          "dosage": {
            "starting dose": "24/26 mg, twice daily",
            "tolerant starting dose": "49/51 mg, twice daily",
            "dose adjustment": "uptitrate dose every 2 to 4 weeks to next dose",
            "target dose": "97/103 mg twice daily"
          },
          "monitoring": "SBP, renal function, K levels",
          "contraindication": "history of angioedema related to previous ACE inhibitors or ARB",
          "side effects": [
            "hypotension",
            "hyperkalemia",
            "cough",
            "dizziness",
            "renal insufficiency"
          ]
        }
      }
    },
    {
      "ID": "02",
      "therapy abbreviation": "Î²-blocker",
      "therapy name": "beta blockers",
      "entry info": {
        "medication": {
          "clinical name": "bisoprolol fumarate",
          "brand name": "Zebeta",
          "indication": "to aid in the treatment of mild to moderate hypertension",
          "dosage": {
            "target dose": "10 mg daily"
          },
          "monitoring": "blood pressure, heart rate",
          "contraindication": "hyperthyroidism, thyroid disease, acute heart failure, AV block, bradycardia, diabetes mellitus",
          "side effects": [
            "body aches or pain",
            "chest pain",
            "difficult or labored breathing",
            "ear congestion",
            "loss of voice",
            "nasal congestion"
          ]
        }
      }
    },
    {
      "ID": "03",
      "therapy abbreviation": "MRA",
      "therapy name": "mineralocorticoid receptor antagonists",
      "entry info": {
        "medication": {
          "clinical name": "spironolactone",
          "brand name": "Aldactone",
          "indication": "to reduce risk of CV death and HF hospitalization in patients with chronic HF",
          "dosage": {
            "target dose": "12.5 to 50 mg daily"
          },
          "monitoring": "renal function, K levels",
          "contraindication": "advanced renal insufficiency, hyperkalemia with K > 5.5",
          "side effects": [
            "hypotension",
            "hyperkalemia",
            "hyponatremia",
            "dizziness",
            "renal insufficiency"
          ]
        }
      }
    },
    {
      "ID": "04",
      "therapy abbreviation": "SGLT2i",
      "therapy name": "sodium-glucose cotransporter-2 inhibitor",
      "entry info": {
        "medication": {
          "clinical name": "dapagliflozin",
          "brand name": "Farxiga",
          "indication": "to reduce risk of CV death and HF hospitalization in patients with reduced EF",
          "dosage": {
            "target dose": "10 mg daily",
            "dose adjustment": "start lower dose in elderly, renal dysfunction, and marginal BP"
          },
          "monitoring": "renal function (expected to drop within 2 to 4 weeks), BP",
          "contraindication": "severe renal insufficiency (eGFR < 25), type 1 diabetes",
          "side effects": [
            "female genital mycotic infection, UTI, naso-pharangitis",
            "increased urination and discomfort",
            "volume depletion usually low incidence",
            "renal impairment",
            "severe hypoglycemia"
          ]
        }
      }
    }
  ]
}